8-K: Harvard Bioscience Reports Q2 2026 Results, Raises Full-Year Revenue Guidance

Harvard Bioscience announced second quarter 2026 financial results, reporting an 11% year-over-year revenue increase to $22.7 million and raising its full-year revenue guidance.

Summary

• Harvard Bioscience reported second quarter 2026 revenues of $22.7 million, an 11% increase compared to $20.5 million in the prior year's second quarter.
• For the six months ended June 30, 2026, revenues were $43.5 million, up 3.0% from $42.2 million in the same period of 2025.
• The company raised its full-year 2026 revenue growth guidance to 3%-5% year-over-year.
• Adjusted EBITDA for Q2 2026 was $1.7 million, an increase from $1.5 million in Q2 2025.
• Net loss for Q2 2026 was ($2.9) million, compared to a net loss of ($2.3) million in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth and raised guidance indicating improving business momentum, despite a continued net loss.

Positives

• Second quarter revenue grew 11% year-over-year to $22.7 million.
• Full-year 2026 revenue guidance was raised to 3%-5% year-over-year growth.
• Adjusted EBITDA increased to $1.7 million in Q2 2026 from $1.5 million in Q2 2025.
• Adjusted gross margin for the six months ended June 30, 2026, improved to 58.3% from 57.0% in the prior year.
• Strong commercial traction reported across telemetry and cellular and molecular technology (CMT) products.

Negatives

• Net loss for the second quarter of 2026 was ($2.9) million, an increase from ($2.3) million in the prior year's second quarter.
• Net loss for the six months ended June 30, 2026, was ($6.3) million, compared to a net loss of ($52.6) million in the prior year, though the prior year's loss was heavily impacted by a goodwill impairment.
• Cash used in operations was ($0.3) million for the six months ended June 30, 2026, compared to cash provided by operations of $5.7 million in the same period of the prior year.
• Gross margin slightly decreased to 55.6% in Q2 2026 from 56.4% in Q2 2025.

Risks

• The company's most recently filed Annual Report on Form 10-K contains risk factors that could cause actual results to differ materially from forward-looking statements.
• Forward-looking statements are subject to known and unknown uncertainties, risks, assumptions, and contingencies outside the company's control.

Future Outlook

The company is raising its full-year 2026 revenue guidance to 3%-5% year-over-year growth, while maintaining its adjusted EBITDA target. Third quarter 2026 guidance projects mid-single-digit year-over-year revenue growth and improved year-over-year profitability on an adjusted EBITDA basis.

Management Comments

• "We delivered a strong quarter anchored by 11% top-line growth, reflective of stronger demand and an improved environment across our key customer channels."
• "We are seeing solid commercial traction across our telemetry and cellular and molecular technology (CMT) products, driven by our AAA and electroporation businesses, and strong engagement from researchers utilizing our preclinical platform."
• "This strong sales momentum positions us to raise our full-year revenue outlook while maintaining our adjusted EBITDA target, supported by ongoing cost discipline and operational progress."

Industry Context

StockSavvy.ai notes that Harvard Bioscience's reported revenue growth and raised guidance align with a general trend of recovery and increased investment in life sciences research and development, particularly in areas like drug discovery and preclinical testing, following periods of economic uncertainty.

Stakeholder Impact

• Shareholders may see positive impact from raised revenue guidance and improved adjusted EBITDA, potentially signaling a turnaround.
• Employees may benefit from the company's improved commercial traction and operational progress.
• Customers in the life science research, drug discovery, and preclinical testing sectors are likely to continue benefiting from the company's technologies and products.

Next Steps

• Continue to drive commercial traction across telemetry and CMT products.
• Leverage new product innovation (NPI) platforms.
• Maintain cost discipline and operational progress.
• Focus on improving year-over-year profitability on an adjusted EBITDA basis in Q3 2026.

Key Dates

Recommendation

The company shows positive revenue growth and has raised its full-year guidance, which is encouraging. However, the continued net loss and decrease in cash from operations suggest that while momentum is improving, the company is not yet consistently profitable on a GAAP basis. Therefore, a 'hold' recommendation is appropriate pending sustained profitability and further operational improvements.

Keywords

Harvard Bioscience, Q2 2026, Financial Results, Revenue Growth, Adjusted EBITDA, Life Science, Cellular and Molecular Technology, Preclinical Testing